학술논문
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method
Document Type
Article
Author
Haas, M.; Kruger, S.; Westphalen, C.B.; von Bergwelt-Baildon, M.; Boeck, S.; Heinemann, V.; Waldschmidt, D.T.; Stahl, M.; Reinacher-Schick, A.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kaiser, F.; Kanzler, S.; Frickhofen, N.; Seufferlein, T.; Dechow, T.; Mahlberg, R.; Malfertheiner, P.; Illerhaus, G.; Kubicka, S.; Abdul-Ahad, A.; Snijder, R.; Held, S.
Source
In: European Journal of Cancer . (European Journal of Cancer, March 2021, 146:95-106)
Subject
Language
English
ISSN
18790852
09598049
09598049